Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy

  • Letter to the Editor
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Yannuzzi LA (2010) Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 149:361–363

    Article  PubMed  Google Scholar 

  2. Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S (2003) Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 23:1–7, quiz 137–138

    Article  PubMed  Google Scholar 

  3. Kim YY, Flaxel CJ (2011) Factors influencing the visual acuity of chronic central serous chorioretinopathy. Korean J Ophthalmol 25:90–97

    Article  PubMed Central  PubMed  Google Scholar 

  4. Pikkel J, Rumlet S (2012) Intravitreal bevacizumab for choroidal neovascularisation secondary to laser photocoagulation for central serous chorioretinopathy. Eur J Ophthalmol 22:488–491

  5. Konstantinidis L, Mantel I, Zografos L, Ambresin A (2010) Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. Eur J Ophthalmol 20:955–958

  6. Kumar N, Marsiglia M, Mrejen S et al (2013) Visual and anatomical outcomes of intrvitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605–1612

    Article  CAS  PubMed  Google Scholar 

  7. Chang AA et al (2014) Intravitreal aflibercept for treatment resistant neovascular age-related macular degeneration. Ophthalmology 121:188–192

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No funding support was received for this work. Dr Broadhead has no conflicts of interest associated with this submission. Dr Chang has acted as a consultant and has received grants from Bayer, Novartis, and Alcon. Dr Chang had full access to all data in this study, and takes responsibility for the integrity of the data and accuracy of the data analysis.

All patients provided informed consent prior to their inclusion in this study.

Author information

Authors and Affiliations

  1. Sydney Retina Clinic & Day Surgery, Sydney, Australia

    Geoffrey K. Broadhead & Andrew Chang

  2. Sydney Institute of Vision Science, Level 13, Park House, 187 Macquarie Street, Sydney, NSW, 2000, Australia

    Geoffrey K. Broadhead & Andrew Chang

Authors
  1. Geoffrey K. Broadhead
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Chang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Broadhead, G.K., Chang, A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 253, 979–981 (2015). https://doi.org/10.1007/s00417-014-2891-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-014-2891-0

Keywords

Search

Navigation